Pure Global
NCT03903081

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single & Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects
Sunshine Lake Pharma Co., Ltd.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
HEC110114 tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sunshine Lake Pharma Co., Ltd.
Location
Changchun, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 06, 2019
End date
Oct 29, 2019
Enrollment
93 participants
Primary outcome

Adverse Events

Summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single & Multiple
 Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in
 Healthy Adult Subjects

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03903081
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03903081 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 93 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.